Table 3 Plasma concentrations of darunavir and elvitegravir at 24 h post-dose
Study intervention | N | Darunavir Ctrough,ss, ng/mL | Elvitegravir Ctrough,ss, ng/mL | Refs. | ||
|---|---|---|---|---|---|---|
Median/mean | Range | Median/mean | Range | |||
DRV/rtv, pre-switch | 5 | 981 (median) 932 (mean) | 667–1150 | – – | – |  |
E/C/F/TDF + DRV | 9 | 482 (median) 490 (mean) | 96–848 | 184 (median) 200 (mean) | <  80–435 |  |
DRV/rtv 800/100 mg | 335a | 2041 (median) | 368–7242 | – | – | [22] |
119 | 1820 (mean) | IQR 1470–2460 | – | – | [23] | |
DRV/cobi 800/150 mg | 298a | 2150 (mean) | SD 1320 | – | – | [25] |
59 | 1311 (mean) | SD 969 | – | – | [25] | |
32 | 1319 (mean) | 288–3641 | – | – | [24] | |
E/C/F/TDF (no DRV) | 419a | – | – | 451 (mean) | 58–2341 | [26] |
32 | – | – | 250 (mean) | 30–762 | [24] | |
E/C/F/TDF + DRV | 24 | 1294 (mean) | 163–3641 | 234 (mean) | 92–432 | [24] |
8 | 273 (median)b | 164–501 (IQR)b | – | – | [12] | |
E/C/F/TAF + DRV | 15 | 1250 (mean) | NA | 464 (mean) | NA | [36] |